66 related articles for article (PubMed ID: 25738850)
1. A phase I safety and pharmacokinetic study of ATX-101: injectable, synthetic deoxycholic acid for submental contouring.
Walker P; Fellmann J; Lizzul PF
J Drugs Dermatol; 2015 Mar; 14(3):279-87. PubMed ID: 25738850
[TBL] [Abstract][Full Text] [Related]
2. Improvement in Jowl Fat following ATX-101 Treatment: Results from a Single-Site Study.
Shridharani SM
Plast Reconstr Surg; 2020 Apr; 145(4):929-935. PubMed ID: 32221205
[TBL] [Abstract][Full Text] [Related]
3. Results from a pooled analysis of two European, randomized, placebo-controlled, phase 3 studies of ATX-101 for the pharmacologic reduction of excess submental fat.
McDiarmid J; Ruiz JB; Lee D; Lippert S; Hartisch C; Havlickova B
Aesthetic Plast Surg; 2014 Oct; 38(5):849-60. PubMed ID: 24984785
[TBL] [Abstract][Full Text] [Related]
4. How We Do It: Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat.
Goldman MP; Ishii L; Zubair R; Wu DC
Dermatol Surg; 2023 Sep; 49(9):903-906. PubMed ID: 37318154
[No Abstract] [Full Text] [Related]
5. Quantifiable Changes in the Submental Area and Mandible Border After Dual-Modality Treatment With ATX-101 and VYC-20L for Overall Improvement in Jawline Contour.
Goodman GJ; Roberts S; Cook N; Ashton M; Nie R; Alker L; Silberberg M
J Drugs Dermatol; 2024 Jan; 23(1):1325-1331. PubMed ID: 38206149
[TBL] [Abstract][Full Text] [Related]
6. Lipolytic agents for submental fat reduction: Review.
Park SY; Kim SB; Wan J; Felice F; Yi KH
Skin Res Technol; 2024 Feb; 30(2):e13601. PubMed ID: 38297988
[TBL] [Abstract][Full Text] [Related]
7. A novel approach for deoxycholic acid administration to treat submental fullness: A case report assessed by 3D stereophotogrammetry.
Rogerio V; Rabelo V; Roschel P; Sakemi T; Germani M; Munoz-Lora VRM
J Oral Biol Craniofac Res; 2024; 14(3):280-283. PubMed ID: 38586285
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the enzymatic mixture - Lipase, collagenase and hyaluronidase - In the treatment of moderate to severe submental fat: A prospective cohort study.
Jabbour R; Farah F; Mallat F; Saad E; Semaan K; Haber R; Helou J
Heliyon; 2024 Feb; 10(4):e25759. PubMed ID: 38375282
[TBL] [Abstract][Full Text] [Related]
9. REFINE-1, a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial With ATX-101, an Injectable Drug for Submental Fat Reduction.
Jones DH; Carruthers J; Joseph JH; Callender VD; Walker P; Lee DR; Subramanian M; Lizzul PF; Gross TM; Beddingfield FC
Dermatol Surg; 2016 Jan; 42(1):38-49. PubMed ID: 26673433
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical Approval Update.
Gohil K
P T; 2015 Jul; 40(7):427-9. PubMed ID: 26185402
[TBL] [Abstract][Full Text] [Related]
11. ATX-101 for reduction of submental fat: A phase III randomized controlled trial.
Humphrey S; Sykes J; Kantor J; Bertucci V; Walker P; Lee DR; Lizzul PF; Gross TM; Beddingfield FC
J Am Acad Dermatol; 2016 Oct; 75(4):788-797.e7. PubMed ID: 27430612
[TBL] [Abstract][Full Text] [Related]
12. Overview of ATX-101 (Deoxycholic Acid Injection): A Nonsurgical Approach for Reduction of Submental Fat.
Dayan SH; Humphrey S; Jones DH; Lizzul PF; Gross TM; Stauffer K; Beddingfield FC
Dermatol Surg; 2016 Nov; 42 Suppl 1():S263-S270. PubMed ID: 27787266
[TBL] [Abstract][Full Text] [Related]
13. Formulations of deoxycholic for therapy: a patent review (2011 - 2014).
Hwang SR; Kim IJ; Park JW
Expert Opin Ther Pat; 2015; 25(12):1423-40. PubMed ID: 26485465
[TBL] [Abstract][Full Text] [Related]
14. Prevention and Management of Injection-Related Adverse Effects in Facial Aesthetics: Considerations for ATX-101 (Deoxycholic Acid Injection) Treatment.
Fagien S; McChesney P; Subramanian M; Jones DH
Dermatol Surg; 2016 Nov; 42 Suppl 1():S300-S304. PubMed ID: 27787270
[TBL] [Abstract][Full Text] [Related]
15. Proper Technique for Administration of ATX-101 (Deoxycholic Acid Injection): Insights From an Injection Practicum and Roundtable Discussion.
Jones DH; Kenkel JM; Fagien S; Glaser DA; Monheit GD; Stauffer K; Sykes JM
Dermatol Surg; 2016 Nov; 42 Suppl 1():S275-S281. PubMed ID: 27787267
[TBL] [Abstract][Full Text] [Related]
16. [The use of deoxycholic acid (ATX-101) in aesthetic medicine: A promising treatment].
Hersant B; Calmon A; Meningaud JP
Rev Stomatol Chir Maxillofac Chir Orale; 2015 Dec; 116(6):350-2. PubMed ID: 26598242
[TBL] [Abstract][Full Text] [Related]
17. What Does the Data from the ATX-101 Phase I Safety and Pharmacokinetic Study Tell Us?
Jagdeo J
J Drugs Dermatol; 2015 Jun; 14(6):544-5. PubMed ID: 26091376
[No Abstract] [Full Text] [Related]
18. Management of Patient Experience With ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat.
Dover JS; Kenkel JM; Carruthers A; Lizzul PF; Gross TM; Subramanian M; Beddingfield FC
Dermatol Surg; 2016 Nov; 42 Suppl 1():S288-S299. PubMed ID: 27787269
[TBL] [Abstract][Full Text] [Related]
19. A Double-Blind, Placebo-Controlled, Phase 3b Study of ATX-101 for Reduction of Mild or Extreme Submental Fat.
Glogau RG; Glaser DA; Callender VD; Yoelin S; Dover JS; Green JB; Breshears L; Bowen B
Dermatol Surg; 2019 Dec; 45(12):1531-1541. PubMed ID: 30998531
[TBL] [Abstract][Full Text] [Related]
20. Sodium Deoxycholate for Submental Contouring.
Humphrey S; Beleznay K; Beleznay JD
Skin Therapy Lett; 2016 Sep; 21(5):1-4. PubMed ID: 27603325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
